Pulmonary Hypertension Supportive Care Protocol

Pulmonary hypertension (PH) is high blood pressure in the blood vessels of the lungs. Unlike regular high blood pressure (systemic), PH specifically affects the pulmonary arteries. This increases the workload on the right side of the heart, which can eventually lead to right heart failure. Symptoms include shortness of breath (especially with exertion), fatigue, chest pain, dizziness, leg swelling, and racing heartbeat.

CRITICAL: Pulmonary hypertension is a serious, life-threatening condition requiring specialist care from a pulmonologist and/or cardiologist experienced in PH. There are 5 groups of PH with different causes and treatments:

•Group 1 (PAH): Pulmonary arterial hypertension - treated with targeted therapies

•Group 2: Due to left heart disease

•Group 3: Due to lung disease/hypoxia

•Group 4: Chronic thromboembolic (CTEPH)

•Group 5: Unclear/multifactorial

MEDICAL TREATMENT IS ESSENTIAL. For Group 1 PAH, approved therapies include: phosphodiesterase inhibitors (sildenafil, tadalafil), endothelin receptor antagonists (bosentan, ambrisentan), prostacyclin analogs (epoprostenol, treprostinil), and soluble guanylate cyclase stimulators (riociguat). Treatment is complex and often involves combination therapy.

These supplements are SUPPORTIVE ONLY and must be discussed with your PH specialist:

* Iron deficiency is extremely common in PAH (affecting 40-60% of patients) and independently worsens exercise capacity. IV iron replacement (oral often ineffective) can significantly improve symptoms.

* Coenzyme Q10 supports heart energy production.

* Omega-3 Fatty Acids may support vascular health.

* L-Arginine is a nitric oxide precursor - use ONLY under physician supervision as it can interact with PH medications.

* Magnesium and L-Carnitine support cardiovascular function.

Expected outcomes: These supplements may provide modest supportive benefit but DO NOT replace medical therapy. Work closely with your PH specialist team.

Clinical Perspective

Pulmonary Hypertension: mean pulmonary artery pressure >20 mmHg at rest (by right heart catheterization). Classification: Group 1 - PAH (idiopathic, heritable, drug-induced, CTD-associated, HIV, portal HTN, CHD); Group 2 - left heart disease (HFrEF, HFpEF, valvular); Group 3 - lung disease/hypoxia (COPD, ILD, OSA); Group 4 - CTEPH; Group 5 - multifactorial. Pathophysiology: vasoconstriction, remodeling, thrombosis → increased PVR → RV failure.

CRITICAL: Specialist management mandatory. Evaluation: echocardiography (screening), RHC (confirmation), 6MWT (functional capacity), BNP/NT-proBNP, pulmonary function tests, V/Q scan (CTEPH), HRCT, autoimmune serologies. Treatment based on group and risk stratification. PAH: upfront dual oral therapy (ERA + PDE5i) for most; triple therapy including prostanoid for high-risk; IV prostacyclin for severe disease. Atrial septostomy or lung transplant for refractory. Group 2-3: treat underlying condition; PAH drugs generally not indicated (may worsen). CTEPH: pulmonary endarterectomy if operable; balloon angioplasty or riociguat if not. Supplements are ADJUNCTIVE.

* Coenzyme Q10 (C-grade): Cardiac energetics. Pilot study: PAH (PMID: 26891673). 100-300mg daily.

* Iron (B-grade): Deficiency very common (40-60%); worsens outcomes. Systematic review: (PMID: 25600306). Clinical trial: IV iron (PMID: 21285278). IV iron if deficient; oral often insufficient.

* Omega-3 Fatty Acids (C-grade): Vascular health. Review: (PMID: 27837121). 2-3g EPA+DHA daily.

* Vitamin D (C-grade): Common deficiency. Study: PH (PMID: 28011217). 2000-4000 IU daily.

* L-Arginine (C-grade): NO precursor. Review: PH (PMID: 17008558). 3-6g daily. CAUTION: discuss with physician; potential interactions with PDE5 inhibitors.

* Magnesium (C-grade): CV support. Systematic review: (PMID: 27383068). 300-400mg daily.

* L-Carnitine (C-grade): Cardiac metabolism. Review: (PMID: 24140491). 1-2g daily.

* B-Complex (C-grade): Energy metabolism. Review: (PMID: 17696772). Daily.

* Taurine (C-grade): Cardiac support. Review: (PMID: 26197117). 1-3g daily.

Assessment targets: 6-minute walk distance, WHO functional class, BNP/NT-proBNP, echocardiography (RV function, TAPSE, pericardial effusion), hemodynamics (RHC), quality of life.

Protocol notes: Iron: IV preferred (ferric carboxymaltose); check ferritin, TSAT; target ferritin >100, TSAT >20%; oral iron poorly absorbed in PH. Diuretics: essential for fluid management; loop diuretics; monitor electrolytes. Oxygen: supplemental O2 if hypoxic; target SpO2 >90%. Exercise: supervised rehabilitation beneficial; avoid isometric exercises. Altitude: avoid high altitude (>1500m) without supplemental O2. Pregnancy: contraindicated in PAH (maternal mortality 30-50%); effective contraception essential; estrogen-free methods preferred. Vaccinations: influenza and pneumococcal recommended. Anticoagulation: controversial; historically used in IPAH; now individualized. CTEPH: always consider; V/Q scan screening; surgical PEA potentially curative. Drug interactions: sildenafil/tadalafil with nitrates contraindicated; ERA liver monitoring; prostanoids require careful titration. Palliative care: early involvement beneficial given prognosis. Patient registries: consider enrollment (REVEAL, COMPERA). Support groups: Pulmonary Hypertension Association resources. Prognosis: improved with modern therapies; 5-year survival ~60-70% for PAH with treatment.

View All Protocols